MCT8 - AHDS Foundation

Beneficial Effects of Propylthiouracil plus L-Thyroxine Treatment in a Patient with a Mutation in MCT8

J. L. We´ meau, M. Pigeyre, E. Proust-Lemoine, M. d’Herbomez, F. Gottrand, J. Jansen, T. J. Visser, and M. Ladsous

Context: Mutations of the monocarboxylate transporter 8 (MCT8) gene determine a distinct Xlinked phenotype of severe psychomotor retardation and consistently elevated T3 levels. Lack of MCT8 transport of T3 in neurons could explain the neurological phenotype.

Objective: Our objective was to determine whether the high T3 levels could also contribute to some critical features observed in these patients.

Results: A 16-yr-old boy with severe psychomotor retardation and hypotonia was hospitalized for malnutrition (body weight25 kg) and delayed puberty. He had tachycardia (104 beats/min), high SHBG level (261 nmol/liter), and elevated serum free T3 (FT3) level (11.3 pmol/liter), without FT4 and TSH abnormalities. A missense mutation of the MCT8 gene was present. Oral overfeeding was unsuccessful.Thetherapeutic effect of propylthiouracil (PTU)andthenPTUplus levothyroxine (LT4) wastested. AfterPTU(200 mg/d), serum FT4wasundetectable, FT3wasreduced (3.1 pmol/liter) with high TSH levels (50.1 mU/liter). Serum SHBG levels were reduced (72 nmol/liter). While PTU prescription was continued, high LT4 doses (100g/d) were needed to normalize serum TSH levels (3.18 mU/liter). At that time, serum FT4 was normal (16.4 pmol/liter), and FT3 was slightly high (6.6 pmol/liter). Tachycardia was abated (84 beats/min), weight gain was 3 kg in 1 yr, and SHBG was 102 nmol/liter.

Conclusions: 1) When thyroid hormone production was reduced by PTU, high doses of LT4 (3.7 g/kgd) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone. 2) High T3 levels might exhibit some deleterious effects on adipose, hepatic, and cardiac levels. 3) PTU plus LT4 could be an effective therapy to reduce general adverse features, unfortunately without benefit on the psychomotor retardation. (J Clin Endocrinol Metab 93: 2084–2088, 2008)